Searchable abstracts of presentations at key conferences in endocrinology

ea0073yi4 | Young Investigator Awards | ECE2021

Use of 11C-methionine PET-CT scanning to guide management of acromegaly following primary therapy – A pragmatic prioritisation strategy to achieve maximal cost effectiveness

Rajan Roby , Bhatt D , Philip S , Graveling AJ , Kamel M , Olson S , Mckiddie F , Gillett D , Bashari W , Gurnell M , Abraham P

Background11C-methionine (11C-Met) positron emission tomography co-registered with MRI is a new imaging technique used for functioning pituitary adenomas, permitting targeted intervention (Transphenoidal Surgery (TSS) or Radiotherapy)1. The 11C-Met PET-CT scan has been available in our centre since Dec 2016. With limited availability in 2019/2020 (due to cyclotron refurbishment) we re-audited our patients to prioritise th...

ea0007p47 | Diabetes, metabolism and cardiovascular | BES2004

A novel non-steroidal inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 improves features of metabolic syndrome in murine disease models

Thieringer R , Balkovec J , Chen H , Frazier E , Le Grand C , Li Z , Metzger J , Mundt S , Nunes C , Strowski M , Olson S , Robertson N , Strack A , Schaeffer J , Wright S , Zhang B , Hermanowski-Votska A

Chronic exposure to elevated circulating glucocorticoids can lead to metabolic changes, which resemble those observed in Metabolic Syndrome. Features of the Metabolic Syndrome can be reversed by lowering systemic glucocorticoid levels or by treatment with a glucocorticoid receptor antagonist. At the intracellular level, exposure to glucocorticoids is regulated by two distinct 11beta-hydroxysteroid dehydrogenases, 11beta-HSD type 1 and type 2. 11beta-HSD1 predominantly acts as ...